ClinicalTrials.gg
CompletedNCT00528840JOINT-IUpdated Dec 2, 2017Results posted

Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

A Phase 3 interventional study of collagenase clostridium histolyticum in Advanced Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This was a Phase 3, 9-month, open-label study conducted in the United States. Subjects with a diagnosis of advanced Dupuytren's disease in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint that resulted in a fixed flexion deformity of at least one finger, other than the thumb, that was at least 20° as measured by finger goniometry and was suitable for evaluation and injection were enrolled.

This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.

02

Conditions studied

  • Advanced Dupuytren's Disease
03

In context

Lead sponsor

Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.

First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
  • Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
  • Were naïve to AA4500 treatment or had received one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in Auxilium Studies AUX-CC-851, AUX-CC-853, or AUX-CC-855.
  • Were judged to be in good health.

Exclusion criteria

Exclusion Criteria:

  • Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
  • Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.
  • Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    AA4500 0.58 mg

    Biological: collagenase clostridium histolyticum

Interventions

  • Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.

    Also known as: XIAFLEX®, AA4500

06

What researchers measure

Primary outcomes

  1. Reduction in Contracture to 5° or Less

    The Primary Outcome Measure is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection

    Time frame: Within 30 days after the last injection

Secondary outcomes

  1. Clinical Improvement After the Last Injection

    Clinical Improvement is defined as \>=50% percent reduction from baseline in degree of contracture within 30 days after injection.

    Time frame: Baseline; within 30 days after last injection

  2. Percent Reduction From Baseline Contracture After the Last Injection

    Percent change in degree of contracture measured as 100\*(baseline contracture -last available post-injection contracture)/baseline contracture)

    Time frame: Baseline, within 30 days after last injection

  3. Change From Baseline Range of Motion After the Last Injection

    Change in degree of range of motion measured as last available post-injection range of motion - baseline range of motion.

    Time frame: Baseline, 30 days after last injection

  4. Time to Reach Clinical Success

    Clinical success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection, displayed in post-injection timepoint categories.

    Time frame: First evaluation visit on which clinical success is achieved through the Day 30 evaluation

  5. Clinical Success After the First Injection

    Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.

    Time frame: Within 30 days after first injection

  6. Clinical Improvement After the First Injection

    Clinical Improvement is defined as \>=50% reduction from baseline in the degree of contracture within 30 days after the first injection

    Time frame: Baseline; within 30 days after first injection

  7. Percent Reduction From Baseline Contracture After the First Injection

    Percent change in degree of contracture is measured as 100\* (baseline contracture- last available post-injection contracture)/baseline contracture.

    Time frame: Baseline; within 30 days after first injection

  8. Change From Baseline Range of Motion After the First Injection

    Change in degree of range of motion measured as last available post-injection range of motion-baseline range of motion.

    Time frame: Baseline; within 30 days after first injection

07

Results

Posted Oct 22, 2010

Participant flow

Participant flow — Overall Study
MilestoneAA4500 0.58 mg
Started201
Completed168
Not completed33
Withdrew: Lost to follow-up10
Withdrew: Adverse event1
Withdrew: Withdrawal by subject17
Withdrew: Death2
Withdrew: Administrative reasons1
Withdrew: Other2

Outcome measures

PrimaryReduction in Contracture to 5° or Less

The Primary Outcome Measure is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection

Time frame:
Within 30 days after the last injection
Reported as:
Number · percentage of joints
Reduction in Contracture to 5° or Less
percentage of jointsAA4500 0.58 mg
Reduction in Contracture to 5° or Less52.7
SecondaryClinical Improvement After the Last Injection

Clinical Improvement is defined as \>=50% percent reduction from baseline in degree of contracture within 30 days after injection.

Time frame:
Baseline; within 30 days after last injection
Reported as:
Number · percent of joints
Clinical Improvement After the Last Injection
percent of jointsAA4500 0.58 mg
Clinical Improvement After the Last Injection71.6
SecondaryPercent Reduction From Baseline Contracture After the Last Injection

Percent change in degree of contracture measured as 100\*(baseline contracture -last available post-injection contracture)/baseline contracture)

Time frame:
Baseline, within 30 days after last injection
Reported as:
Mean · percentage of joints
Percent Reduction From Baseline Contracture After the Last Injection
percentage of jointsAA4500 0.58 mg
Percent Reduction From Baseline Contracture After the Last Injection66.8 ± 40.91
SecondaryChange From Baseline Range of Motion After the Last Injection

Change in degree of range of motion measured as last available post-injection range of motion - baseline range of motion.

Time frame:
Baseline, 30 days after last injection
Reported as:
Mean · degrees
Change From Baseline Range of Motion After the Last Injection
degreesAA4500 0.58 mg
Change From Baseline Range of Motion After the Last Injection28.3 ± 20.15
SecondaryTime to Reach Clinical Success

Clinical success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection, displayed in post-injection timepoint categories.

Time frame:
First evaluation visit on which clinical success is achieved through the Day 30 evaluation
Reported as:
Number · percentage of joints
Time to Reach Clinical Success
percentage of jointsAA4500 0.58 mg
Injection 1, Day 19.6
Injection 1, Day 716.4
Injection 1, Day 3016.1
Injection 2, Day 00.0
Injection 2, Day 12.4
Injection 2, Day 72.4
Injection 2, Day 303.1
Injection 3, Day 00.0
Injection 3, Day 10.7
Injection 3, Day 71.0
Injection 3, Day 300.7
Injection 3, Day 900.3
Did not reach clinical success47.3
SecondaryClinical Success After the First Injection

Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.

Time frame:
Within 30 days after first injection
Reported as:
Number · percentage of joints
Clinical Success After the First Injection
percentage of jointsAA4500 0.58 mg
Clinical Success After the First Injection42.5
SecondaryClinical Improvement After the First Injection

Clinical Improvement is defined as \>=50% reduction from baseline in the degree of contracture within 30 days after the first injection

Time frame:
Baseline; within 30 days after first injection
Reported as:
Number · percentage of joints
Clinical Improvement After the First Injection
percentage of jointsAA4500 0.58 mg
Clinical Improvement After the First Injection64.4
SecondaryPercent Reduction From Baseline Contracture After the First Injection

Percent change in degree of contracture is measured as 100\* (baseline contracture- last available post-injection contracture)/baseline contracture.

Time frame:
Baseline; within 30 days after first injection
Reported as:
Mean · percentage of change
Percent Reduction From Baseline Contracture After the First Injection
percentage of changeAA4500 0.58 mg
Percent Reduction From Baseline Contracture After the First Injection60.4 ± 39.38
SecondaryChange From Baseline Range of Motion After the First Injection

Change in degree of range of motion measured as last available post-injection range of motion-baseline range of motion.

Time frame:
Baseline; within 30 days after first injection
Reported as:
Mean · degrees
Change From Baseline Range of Motion After the First Injection
degreesAA4500 0.58 mg
Change From Baseline Range of Motion After the First Injection25.3 ± 19.52

Adverse events

Collected over Non-serious adverse events (non-SAEs) were collected from time of study drug administration, serious adverse events (SAEs) were collected from time subject signed ICF. Non-SAEs & SAEs were collected until 30 days after completion or discharge from study.. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.58 mg—11/201 (5.5%)197/201 (98%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventAA4500 0.58 mg
Myocardial infarctionCardiac disorders2/201
Acute myocardial infarctionCardiac disorders1/201
Atrial fibrillationCardiac disorders1/201
Chest painGeneral disorders1/201
Clavicle fractureInjury, poisoning and procedural complications1/201
Compression fractureInjury, poisoning and procedural complications1/201
Deep vein thrombosisVascular disorders1/201
EmbolismVascular disorders1/201
Enterococcal sepsisInfections and infestations1/201
FallInjury, poisoning and procedural complications1/201
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAA4500 0.58 mg
Oedema peripheralGeneral disorders151/201
Injection site painGeneral disorders116/201
Injection site haemorrhageGeneral disorders109/201
ContusionInjury, poisoning and procedural complications100/201
Injection site swellingGeneral disorders57/201
Pain in extremityMusculoskeletal and connective tissue disorders48/201
TendernessGeneral disorders48/201
EcchymosisSkin and subcutaneous tissue disorders43/201
Skin lacerationInjury, poisoning and procedural complications32/201
PruritusSkin and subcutaneous tissue disorders24/201

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500 0.58 mg
<=18 years0
Between 18 and 65 years95
>=65 years106
Age, Continuous
Age, Continuous(years)AA4500 0.58 mg
Mean64.7 ± 9.86
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.58 mg
Female37
Male164
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AA4500 0.58 mg
White201
Region of Enrollment
Region of Enrollment(participants)AA4500 0.58 mg
United States201
08

Study locations

14 sites
  • Hope Research Institute
    Phoenix, Arizona 85050, United States
  • Tucson Orthopedic Institute, P.C.
    Tucson, Arizona 85172, United States
  • Providence Clinical Research
    Burbank, California 91505, United States
  • Southern Illinois Hand Center, S.C.
    Effingham, Illinois 62401, United States
  • Rockford Orthopedic Associates, Ltd.
    Rockford, Illinois 61107, United States
  • The Indiana Hand Center
    Indianapolis, Indiana 46260, United States
  • Pri Via
    Wichita, Kansas 67214, United States
  • St. Alexius Medical Center
    Bismarck, North Dakota 58501, United States
  • David R. Mandel, Inc.
    Mayfield, Ohio 44143, United States
  • St. Vincent Medical Center
    Portland, Oregon 97225, United States
  • Hamot Center for Clinical Research
    Erie, Pennsylvania 16550, United States
  • Alpha Clinical Research
    Clarksville, Tennessee 37043, United States
  • The Rheumatic Disease Clinic of Houston
    Houston, Texas 77004, United States
  • Accurate Clincal Research
    Houston, Texas 77034, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2007 to primary completion in Oct 2008, 12 months.

Results were first posted in Oct 2010, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2007
First posted
Sep 12, 2007
StartActual
Oct 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Oct 22, 2010
Last update
Dec 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00528840
Responsible party
Sponsor
First posted
Sep 12, 2007
Start date
Oct 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Oct 22, 2010
Last update
Dec 2, 2017

Study contacts

Veronica Urdaneta, MD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion